Lindsey Rolfe
Director/Board Member bei ATRECA, INC.
Vermögen: - $ am 31.03.2024
Profil
Lindsey Rolfe is an Independent Director at Atreca, Inc. and CERo Therapeutics Holdings, Inc. They are also a Member at The Royal College of Physicians.
Previously, Dr. Rolfe worked as the Chief Medical Officer & Executive VP-Clinical at Clovis Oncology, Inc. Dr. Rolfe holds a doctorate degree from The University of Edinburgh.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ATRECA, INC. CLASS A
-.--% | 13.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
-.--% | 05.04.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Lindsey Rolfe
| Unternehmen | Position | Beginn |
|---|---|---|
| ATRECA, INC. | Director/Board Member | 22.08.2019 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Lindsey Rolfe
| Unternehmen | Position | Ende |
|---|---|---|
| CLOVIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 01.06.2023 |
Ausbildung von Lindsey Rolfe
| The University of Edinburgh | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ATRECA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
